Khadka Aarju, Subedi Sachet, Lama Nisha, Bhattarai Indu, Deuba Chandrashekhar, Khatri Uttam, Regmi Nisha
College of Medical Sciences Teaching Hospital Bharatpur Nepal.
Tribhuvan University Institute of Medicine, Maharajgunj Medical Campus Chitwan Nepal.
Clin Case Rep. 2025 Mar 7;13(3):e70303. doi: 10.1002/ccr3.70303. eCollection 2025 Mar.
Primaquine, an antimalarial drug, is essential for preventing relapses of . However, it poses a risk of hemolytic anemia, particularly in glucose-6-phosphate dehydrogenase (G6PD) deficient patients. This case report details a 27-year-old male with normal G6PD levels who developed hemolytic anemia following primaquine therapy for malaria. Despite a normal quantitative G6PD analysis, the patient experienced a significant drop in hemoglobin, necessitating early discontinuation of the drug. This case highlights the potential for hemolysis in G6PD-normal patients, underscoring the importance of close monitoring and the limitations of current G6PD screening methods.
伯氨喹是一种抗疟药物，对于预防[疾病名称]的复发至关重要。然而，它存在导致溶血性贫血的风险，尤其是在葡萄糖-6-磷酸脱氢酶（G6PD）缺乏的患者中。本病例报告详细描述了一名27岁男性，其G6PD水平正常，在接受伯氨喹治疗疟疾后发生了溶血性贫血。尽管定量G6PD分析结果正常，但患者的血红蛋白显著下降，因此必须提前停药。该病例突出了G6PD正常的患者发生溶血的可能性，强调了密切监测的重要性以及当前G6PD筛查方法的局限性。
